Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.
A new inhaled therapy targeting lung inflammation shows promise in reducing damage and improving recovery after severe ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...
University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...
All eyes were on Crown Princess Mette-Marit of Norway during an unexpected family reunion on Friday. The nation’s future ...
Father-of-one Evan Wilson missed out of his son’s first Christmas and will likely miss out on his first birthday as well.
A new inhaled therapy targets ANGPTL4 to reduce lung inflammation, fluid buildup, and scarring after infections. Preclinical ...
Nanyang Technological University, Singapore (NTU Singapore) is working with China’s Southern University of Science and ...
Nerandomilast may represent a meaningful addition to the treatment arsenal, offering patients and clinicians a new option for pulmonary fibrosis. A new systematic review and meta-analysis suggests ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results